TARGET AUDIENCE
This activity is intended for medical oncologists, hematologists-oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of pancreatic cancer.

OVERVIEW OF ACTIVITY
Pancreatic cancer is the fourth most common cause of cancer-related death among US men and women. The overwhelming majority of pancreatic cancers are ductal adenocarcinomas (approximately 90%). Unfortunately, many patients diagnosed with pancreatic adenocarcinoma (PAD) do not exhibit disease-specific symptoms (eg, weight loss, jaundice, pain, dyspepsia, nausea) until the cancer has reached a more advanced stage, and for all stages of PAD the combined 1-year survival rate for patients who do not receive surgery is approximately 29% and the 5-year rate is an appalling 7%. Published results from ongoing trials have led to the emergence of new therapeutic targets and regimens, and the poor clinical course for many patients with progressive PAD mandates the investigation of even more new approaches. In order to offer optimal patient care — including the option of clinical trial participation — the practicing medical oncologist must be well informed of these advances. To bridge the gap between research and patient care, Pancreatic Cancer Update presents one-on-one discussions with leading gastrointestinal oncology investigators. By providing access to the latest scientific developments and the perspectives of experts in the field, this CME activity assists medical oncologists with the formulation of up-to-date management strategies.

LEARNING OBJECTIVES

• Develop an evidence-based strategy for the treatment of resectable or borderline-resectable PAD, exploring the role of neoadjuvant and adjuvant chemotherapy and/or radiation therapy.
• Consider age, performance status and other clinical and logistical factors in the selection of systemic therapy for patients with locally advanced or metastatic PAD.
• Educate patients with PAD about the potential side effects of various chemotherapeutic regimens, and provide preventive and emergent strategies to reduce or ameliorate these toxicities.
• Appreciate the efficacy and tolerability profile of nanoliposomal irinotecan for treatment-refractory metastatic PAD, and optimally incorporate this agent into patient-care algorithms.
• Recall available and emerging data with other investigational agents currently in clinical testing for PAD and, where applicable, refer eligible patients for trial participation.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
CME credit is no longer available for this issue

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
CME credit is no longer available for this issue

HOW TO USE THIS CME ACTIVITY
Audio Program: This CME activity consists of an audio component.
CME credit is no longer available for this issue

Video Program: This CME activity consists of a video component.
CME credit is no longer available for this issue

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Philip A Philip, MD, PhD
Professor of Oncology and Pharmacology
Director of GI and Neuroendocrine Tumors
Vice President of Medical Affairs
Karmanos Cancer Institute
Wayne State University
Detroit, Michigan

Advisory Committee: Bayer HealthCare Pharmaceuticals, Celgene Corporation, Genentech BioOncology, Halozyme Inc, Lilly, Merrimack Pharmaceuticals Inc, Novartis; Consulting Agreements: Celgene Corporation, Halozyme Inc, Lilly; Contracted Research: Bayer HealthCare Pharmaceuticals, Celgene Corporation, Lilly, Merck, Novartis; Speakers Bureau: Amgen Inc, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Genentech BioOncology, Lilly, Merrimack Pharmaceuticals Inc, Novartis, Sanofi Genzyme.

Ramesh K Ramanathan, MD
Professor of Medicine
Mayo Clinic College of Medicine
Director, GI Medical Oncology
Mayo Clinic, Arizona
Associate Director, Early Cancer Therapeutics Program
Mayo Clinic Cancer Center
Scottsdale, Arizona

Consulting Agreement: Pharmacyclics Inc, an AbbVie Company; Contracted Research: AbbVie Inc, Berg LLC, Celgene Corporation, Ipsen Biopharmaceuticals Inc, Medimark Scientific, Merck.

EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Celgene Corporation and Ipsen Biopharmaceuticals Inc.

Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
Adobe Flash Player 27 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Last review date: March 2018
Expiration date: March 2019